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Comparative study of the expression of proteins involved in grafts, some cases requiring parathyroidectomy [5, 6].
the cell cycle in renal secondary hyperparathyroidism. The cause of this is unknown, although it is reasonable
Background. In renal hyperparathyroidism, parathyroid cell to hypothesize that persistence of remnant PT cell popu-proliferation seems to play a key role in the progression of the
lations harbor mutations, rendering them at least par-disease. Therefore, G1/S transition, a main cell cycle regulatory
tially refractory to physiologic homeostatic signals.step, could be deregulated in these patients.
Methods. One hundred and one parathyroid glands, taken In both conditions, parathyroid (PT) cell growth regu-
from parathyroidectomies performed on 41 patients on hemo- lation seems to play an important role in the progression
dialysis (HD), and 15 glands, taken from 7 patients with post- of the disease. Currently, there is an important gap intransplantation persistent hyperparathyroidism (HPT), were
the knowledge linking classic PT physiology with recentstudied. Twelve normal parathyroid (PT) glands were used as
advances in our understanding of cell cycle regulationthe control. Biochemical data, immunohistochemical (IHC)
profiles of G1/S transition regulators belonging to the two main at the molecular level [3, 4, 7–9]. For these reasons we
pathways (cyclin D1/p16INK4A/pRb and p14ARF/p53/MDM2), and considered it relevant to address mechanisms involved
proliferation rate (Ki67) were correlated. in PT cell cycle regulation under these circumstances.Results. All of the other proteins differed from normal IHC
Until recently, they remain basically unexplored, espe-profiles in both groups that showed significant higher proliferat-
cially in the case of post-transplantation HPT.ing rates, decreases in p27KIP1, pRb, and cyclin D1, as well
as increases in p16INK4A, p53, MDM2, and p21WAF1 levels, in G1/S transition probably constitutes the main cell cy-
comparison with normal PT glands, with the exception of cyclin cle regulatory step in the majority of cell types, either
D3. Contrary to patients with HPT who were on hemodialysis, reactive or after neoplastic transformation [10]. G1/Sin post-transplantation HPT, consistent correlations between
transition regulators belong to two main interconnectedbiochemical data and IHC profiles were obtained.
pathways: cyclin D1/p16INK4A/pRb and p14ARF/p53/MDM2Conclusion. In both groups IHC profiles of proteins in-
volved in G1/S transition regulation significantly differed from [11, 12]. We, thus, hypothesized that G1/S transition reg-
normal PT glands. The results support partial reversion to ulation could be altered in both pathways. Based on this
normal IHC profile in post-transplantation HPT. premise, and taking into account our own studies on PT
adenomas [13, 14], we set up to systematically explore
immunohistochemical (IHC) profiles of several key pro-
Renal secondary hyperparathyroidism (HPT) is a very teins belonging to the mentioned pathways.
frequent condition that arises in hemodialysis (HD) pa-
tients and ultimately requires parathyroidectomy in a
METHODSsubstantial proportion of cases [1]. Its clinical course and
pathologic evolution have been reasonably well defined, Patients and samples
but its pathogenesis remains incompletely defined [2–4]. For this study we selected 101 PT glands (30 with
On the other hand, persistent post-transplantation HPT diffuse and 71 with nodular hyperplasia) from 41 patients
occurs in a subgroup of patients with functioning renal with HPT on hemodialysis (21 males, 20 females, mean
age 46.7 18.5 years; mean time on hemodialysis: 74.0
40.11 months) and 15 PT glands from 7 patients withKey words: hyperparathyroidism, G1/S, regulation, protein, immuno-
histochemistry, expression. post-transplantation HPT (1 male, 6 females; mean age
51.9  12.3 years; post-transplantation time: 66.5  36.5 2003 by the International Society of Nephrology
S-28
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Table 2. G1/S transition: Post-transplantation HPT versus normal PTTable 1. G1/S transition: HDHPT versus normal PT
HDHPT Normal PT P value Post-transplantation HPT Normal PT P value
pRb 12.32.6 32.74.2 0.05pRb 17.30.8 32.74.2 0.05
Cyclin D1 21.10.7 29.52.1 0.05 Cyclin D1 8.62.4 29.52.1 0.05
Cyclin D3 2.30.7 2.70.9 NSCyclin D3 2.30.2 2.70.9 NS
p16INK4 4.10.3 0 0.05 p16INK4 4.91.1 0 0.05
p27KIP1 44.62.7 55.84.4 NSp27KIP1 32.10.9 55.84.4 0.05
p53 4.80.3 01.2 0.05 p53 4.10.9 01.2 0.05
MDM2 16.71.6 2.12.7 0.05MDM2 10.00.52 2.12.7 0.05
p21WAF1 5.00.3 0.91.6 0.05 p21WAF1 4.21.2 0.91.6 0.05
All values refer to percentage of positive cells and are shown as meanSEM. All values refer to percentage of positive cells and are shown as meanSEM.
Abbreviations are: HPT, hyperparathyroidism; PT, parathyroid; NS, not signifi-Abbreviations are: HDHPT, hemodialyzed patients with hyperparathyroidism;
PT, parathyroid; NS, not significant. P  0.05 is statistically significant. P is not cant. P  0.05 is statistically significant. P is not significant at 0.05.
significant at 0.05.
months), in which total parathyroidectomy and PT auto- with HPT. In contrast, in post-transplantation HPT, pro-
liferation rates (PR) (r0.79), cyclins D1 (r0.98),graft had been performed. The glands were aleatorily
selected from among the largest from each patient. D3 (r  0.99), and p16INK4A (r  0.66) negatively
correlated with serum phosphorus and positively withTwelve normal PT glands, from 6 males and 6 females,
removed in the course of unrelated pathologies, were serum calcium levels (r  0.86, 0.99, 0.99, and 0.74, re-
spectively), while PTH serum levels correlated positivelyused as control. In all the cases, basic laboratory bio-
chemical parameters corresponding to the presurgical with PR (r 0.70) and p16INK4A (r 0.83) and negatively
with pRb (r  0.99), p27KIP1 (r  0.99), and all p53period (calcium, phosphorus, alkaline phosphatase, and
parathyroid hormone [PTH]) were obtained. pathway members (p53: r  0.89; MDM2: r  0.83;
p21WAF1: r  0.86).
Immunohistochemistry
IHC profiles of HD patients with HPT andAfter conventional processing, IHC stainings with
post-transplantation HPT differ from normal PT tissuemonoclonal (Mc) Abs against Ki67 (proliferating rate,
PR), cyclins D1 and D3, pRb, p16INK4, p53, MDM2, PR: In normal PT glands, the PR (0.18  0.09) was
p21WAF1 and p27KIP1, were performed in paraffin sections significantly lower than that obtained in both groups
as previously described [13, 14], with the exception of (Table 1). In PT glands from HD patients with HPT,
cyclin D3. Cyclin D3 was detected with Mc Ab DCS-22 PR (3.60  0.24) was significantly higher compared with
from Novocastra (Newcastle, UK), at 1:50 dilution. Label- post-transplantation HPT (1.25 0.74). In this last group,
ing Index (LI) was measured with a CAS200 BV Cytome- PR correlated negatively with p27KIP1 (r  0.77) and
try Digital Image System (Becton Dickinson, Leiden, pRb (r  0.78) and positively with cyclins D1 (r 
The Netherlands), and was expressed as the percentage 0.89) and D3 (r  0.84) and p16INK4A (r  0.98).
of positive cells. At least 1000 cells in PT glands with With the exception of cyclin D3 and partly p27KIP1, all
diffuse hyperplasia and 1000 cells in each nodule in PT the other proteins differed from normal PT gland IHC
glands with nodular hyperplasia were counted. profiles in both groups.
Cyclin D1/p16INK4A/pRb pathway: Both groups showed
Statistical analysis significant decreases in pRb and cyclin D1, as well as
All the data were expressed as mean  SEM. Statisti- increases in p16INK4A levels, in comparison with normal
cal analysis was carried out with NCSS 2000 statistical PT glands. It was especially remarkable for cyclin D1.
package (Number Cruncher Statistical Systems, Kays- Cyclin D1 levels were significantly lower in post-trans-
ville, UT, USA). Correlation coefficients were calculated plantation HPT than those in HD patients with HPT
using Pearson and Spearman correlations. Analysis of (Table 2). Cyclin D3 did not show significant deviations
variance (ANOVA) was performed by Scheffe or Kruskal- from normal PT glands (Table 3).
Wallis multiple comparison tests when values followed p14ARF/p53/MDM2 pathway: Both groups showed simi-
a normal or non-normal distribution, respectively. Sig- lar results, with a significant downregulation of p27KIP1,
nificance level was always P  0.05. while p53, MDM2, and p21WAF1 were clearly upregulated.
p27KIP1 levels present in post-transplantation HPT, al-
though clearly lower in comparison with normal PTRESULTS
glands, did not achieve statistical significance.Biochemical data correlate with IHC profiles in
post-transplantation HPT but not in HD patients
with HPT DISCUSSION
In renal hyperparathyroidism, PT cell hyperplasia, ei-No correlations were found between biochemical data
and hemodialysis time or IHC profiles in HD patients ther associated with mono- or multiclonal growth, arises
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Table 3. G1/S transition: HDHPT versus post-transplantation HPT ther support to the potential pathogenic role of p27KIP1
in PT proliferative lesions.HDHPT Post-transplantation HPT P
In comparison with HD patients with HPT, post-trans-pRb 17.30.8 12.32.6 NS
Cyclin D1 21.10.7 8.62.4 0.05 plantation HPT patients showed lower cyclin D1 and
Cyclin D3 2.30.2 2.30.7 NS higher p27KIP1 levels. In both groups, progressive pRb
p16INK4 4.10.3 4.91.1 NS
inactivation and p27KIP1 downregulation could play ap27KIP1 32.10.9 44.62.7 0.05
p53 4.80.3 4.10.9 NS main role, allowing PT cell proliferation [20].
MDM2 10.00.52 16.71.6 NS p16INK4A, p53, and p21WAF1 upregulation could also be
p21WAF1 5.00.3 4.21.2 NS
envisioned, based on the absence of recently reported
All values refer to percentage of positive cells and are shown as meanSEM. mutations, as attempts to slow down cell proliferationAbbreviations are: HDHPT, hemodialyzed patients with hyperparathyroidism;
HPT, hyperparathyroidism; NS, not significant. P 0.05 is statistically significant. and/or induce apoptosis and cell senescence as has been
P is not significant at 0.05. proposed previously [12]. p53 overexpression could be
functional [24] and related to MDM2 and p21WAF1 upreg-
ulation found in both groups [25, 26]. These are rather
unusual findings, taking in account the benign nature ofas a result of yet unknown pathogenic events. Until
the disease. They are similar to those previously reportedrecently, several genetic loci have been explored unsuc-
by us in PT adenomas [13]. In PT adenomas, at least,cessfully [2, 3, 15]. Based on comparative genomic hy-
we have discarded the presence of MDM2 genomic am-bridization findings, potential roles for other yet unchar-
plification and suggested the existence of post-transcrip-acterized loci have been recently suggested [4]. The
tional regulatory mechanisms (data from the Interna-development of cell and tissue hyperplasia obviously has
tional Conference on Basic and Clinical Aspects of Cellto be placed in close relation with cell cycle regulation.
Cycle Control, Siena, Italy, 2000).Currently, there is very limited available information
The absence of strong biochemical and IHC correla-concerning cell cycle regulation in PT hyperplasia. In
tions in HD patients with HPT in our study probablythis study, we have systematically explored the IHC ex-
underlie clinical and tissue heterogeneity. In contrast,pression of several key cell cycle proteins in an attempt to
we found significant positive correlations between PR,demonstrate G1/S transition deregulation in HD patients
both cyclins, and p16INK4A, with calcium levels and nega-with HPT and post-transplantation HPT.
tive correlations with serum phosphorus levels in patientsAs a reflection of hyperplasia, PR in PT glands is not
with post-transplantation HPT. In this context it mustgreatly increased. The majority of the studies in PT pa-
be remembered that in our study, patients with post-
thology address only a limited set of cell cycle regulatory
transplantation HPT had consistently higher calcium lev-
proteins. Most of them study PR. They report on PR els (data not shown) and lower cyclin D1 levels compared
increases in PT glands in humans [9, 16–20] and in rats to HD patients with HPT. This is in accordance with
[21], in accordance with our own data. In our series, the experimental data reporting cyclin D1 downregulation
PR found in HD patients with HPT was higher than in in response to increased calcium levels [27]. On the other
those with post-transplantation HPT, and similar to that hand, negative correlations between PR and phosphorus
reported previously by us in PT adenomas [14]. It corre- levels in post-transplantation HPT probably place this
lates with the different clinical background and macro- group in a similar situation to primary hyperparathyroid-
scopic anatomic findings (data not shown). ism and opposite of that found in HD patients with HPT,
Our results in the pRb pathway in HD patients with in which, at least at the beginning, phosphorus retention
HPT are in accordance with increased PR. Cyclin D1 appears to be a key factor in cell proliferation [15, 28].
downregulation is a striking finding, but it should be All of these findings are also in accordance with PTH
interpreted cautiously in the context of high physiologic correlations in post-transplantation HPT.
expression in normal PT glands. The data previously In conclusion, our data confirm the presence of sig-
reported are discordant because some authors have nificant differences in IHC profiles of proteins involved
found cyclin D1 overexpression [9, 22], whereas others in G1/S transition regulation in both groups (HD patients
have not [23]. To reconcile these findings, it should be with HPT and post-transplantation HPT) in comparison
recalled that normal PT glands included as controls in with normal PT glands. They also suggest a “partial re-
some studies come from patients with PT adenomas, in version” to normal G1/S transition regulation in post-
which the tumor expresses high cyclin D1 levels and transplantation HPT, based on the presence of lower
the remnant PT glands probably showing skewed IHC PR and relatively homogeneous IHC and biochemical
profiles. p27KIP1 downregulation has been already re- profiles compared to HD patients with HPT. All these
ported by others [20] and supports high PR found in data should be reinterpreted in the future with a more
these patients. These same authors showed p27KIP1 down- precise knowledge of the pathogenic mechanisms in-
volved in renal HPT.regulation in PT adenomas and carcinomas, lending fur-
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